

Pfizer Limited

The Capital, 1802 / 1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

August 2, 2018

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai - 400 001
Scrip Code: 500680

The Manager, Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
Scrip Symbol: PFIZER

Dear Sirs,

Sub: Unaudited financial results for the quarter ended June 30, 2018.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the unaudited financial results for the quarter ended June 30, 2018, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 11:30 a.m. and concluded at 1:30 p.m.

Also please find enclosed the Limited Review Report by our Auditors M/s. Walker Chandiok & Co LLP, in respect of the above results.

Please take the above on record.

Thanking you,

Yours truly,

For Pfizer Limited



Prajeet Nair
Company Secretary

Encl: A/a

Walker Chandiook & Co LLP


Walker Chandiook & Co LLP
16th Floor, Tower II
Indiabulls Finance Centre
S B Marg, Elphinstone (W)
Mumbai 400013
India

T +91 22 6626 2600
F +91 22 6626 2601

Independent Auditor's Review Report on Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Pfizer Limited

1. We have reviewed the accompanying statement of unaudited financial results ("Statement") of Pfizer Limited ("the Company") for the quarter ended 30 June 2018, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable Indian Accounting Standards specified under Section 133 of the Companies Act, 2013, read with SEBI Circulars CIR/CFD/CMD/15/2015 dated 30 November 2015 and CIR/CFD/FAC/62/2016 dated 5 July 2016, and other recognised accounting practices and policies has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.




Walker Chandiook & Co LLP

4. Attention is drawn to Note 5 to the financial results regarding the figures for the quarter ended 31 March 2018 as reported in these financial results, which are the balancing figures between audited figures in respect of the full financial year and the unaudited published year to date figures up to the end of the third quarter of the previous financial year.
5. The comparative financial results of the Company for the corresponding quarter 30 June 2017 were reviewed by the predecessor auditor, who issued an unmodified review report on those financial results on 29 July 2017.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013



Ashish Gupta

Partner

Membership No. 504662

Place: New Delhi

Date: 2 August 2018



Pfizer Limited

The Capital, 1802 / 1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2018

(₹ in crore except earnings per share)

Particulars	3 months ended 30/06/2018	Preceding 3 months ended 31/03/2018	Corresponding 3 months ended in the previous year 30/06/2017	Previous year ended 31/03/2018
	Unaudited	Audited	Unaudited	Audited
1 Income				
(a) Revenue from Operations	512.31	519.95	432.59	1,980.19
(b) Other income	30.53	31.23	27.27	114.29
Total Income	542.84	551.18	459.86	2,094.48
2 Expenses				
(a) Cost of materials consumed	84.88	110.73	79.73	302.52
(b) Purchases of stock-in-trade	82.88	103.21	121.20	409.65
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	16.68	(19.83)	(58.16)	27.51
(d) Excise duty on sales	-	-	11.68	11.68
(e) Employee benefits expenses	80.65	88.62	80.76	314.29
(f) Finance costs	0.17	(0.12)	0.18	0.42
(g) Depreciation and amortization expenses	18.28	17.27	15.23	66.25
(h) Other expenses	117.11	98.76	120.72	414.25
Total Expenses	400.65	398.64	371.34	1,546.57
3 Profit before tax for the period / year (1 -2)	142.19	152.54	88.52	547.91
4 Tax expense				
(a) Current tax	52.99	38.75	33.20	194.49
(b) Deferred tax	(2.64)	9.28	(1.85)	(6.65)
5 Net Profit for the period/year (3 - 4)	91.84	104.51	57.17	360.07
6 Other Comprehensive Income				
(a) Items that will not be reclassified to profit or loss	0.89	11.46	(0.33)	10.47
(b) Income tax related to items that will not be reclassified to profit or loss	(0.31)	(4.00)	0.11	(3.66)
Other comprehensive income	0.58	7.46	(0.22)	6.81
7 Total Comprehensive Income (5 + 6)	92.42	111.97	56.95	366.88
8 Paid-up equity share capital (Face Value per share ₹10)	45.75	45.75	45.75	45.75
9 Other equity				2,637.45
10 Earnings per share - Basic and Diluted (of ₹10/- each) (not annualised) Computed on the basis of profit for the period / year	20.07	22.84	12.50	78.70



CIN : L24231MH1950PLC008311
✉ contactus.india@pfizer.com
🌐 www.pfizerindia.com




NOTES:

1. The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its Meeting held on August 2, 2018 and were approved and taken on record at the Meeting of the Board of Directors of the Company held on that date.
2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated July 5, 2016. Effective 1 April 2018, the Company adopted Ind AS 115 "Revenue from Contracts with Customers" using the cumulative retrospective transition method. There was no material effect on the financial statements on the adoption of Ind AS 115.
3. The financial results for quarter ended June 30, 2018 have been subjected to limited review by the statutory auditors of the Company. The limited review report does not contain any qualifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company's website - www.pfizerindia.com
4. The review of unaudited financial results for the quarter ended June 30, 2017 was carried out and reported by B S R and Co. LLP, Chartered Accountants (previous statutory auditors), vide their unqualified audit report dated 29 July 2017.
5. The figures for the quarter ended March 31, 2018 as reported in these financial results are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the previous financial year. Also, the figures up to the end of the third quarter were only reviewed and not subjected to audit.
6. The Government of India has implemented Goods and Service Tax (GST) with effect from July 1, 2017 which replaced Excise Duty and various other indirect taxes. Revenue for the quarter ended June 30, 2018 is reported net of GST whereas revenue for the quarter ended June 30, 2017 includes excise duty. Accordingly sales for the period are not comparable.
7. The Company has only one segment which is 'Pharmaceuticals'. Therefore disclosure relating to segments is not applicable and accordingly not made.

August 2, 2018



For Pfizer Limited


S. Sridhar
Managing Director